The Identification of Immunological Biomarkers in Kidney Cancers
暂无分享,去创建一个
R. Montironi | Liang Cheng | M. Scarpelli | T. Gevaert | A. Cimadamore | F. Massari | A. Blanca | Vanessa Henriques | M. Santoni | A. López-Beltran
[1] R. Montironi,et al. Editorial: Emerging Biomarkers in Genitourinary Tumors. , 2019, Current drug metabolism.
[2] Y. Allory,et al. Genito-urinary genomics and emerging biomarkers for immunomodulatory cancer treatment. , 2018, Seminars in cancer biology.
[3] R. Pulido,et al. Potential impact of PD-L1 (SP-142) immunohistochemical heterogeneity in clear cell renal cell carcinoma immunotherapy. , 2018, Pathology, research and practice.
[4] R. Montironi,et al. Immunotherapy in renal cell carcinoma: latest evidence and clinical implications , 2018, Drugs in context.
[5] R. Montironi,et al. Renal cell carcinoma in one year: Going inside the news of 2017 - A report of the main advances in RCC cancer research. , 2018, Cancer treatment reviews.
[6] R. Montironi,et al. Tivozanib for the treatment of renal cell carcinoma , 2018, Expert opinion on pharmacotherapy.
[7] J. Brugarolas,et al. Personalized Management of Advanced Kidney Cancer. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.
[8] S. Signoretti,et al. Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis. , 2018 .
[9] M. Climent,et al. Comprehensive molecular and immunohistochemical analysis of advanced renal cell carcinoma patients treated with mTOR inhibitors. , 2018 .
[10] Bohuslav Melichar,et al. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.
[11] A. Ravaud,et al. IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC) , 2018 .
[12] Laurence Zitvogel,et al. Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors , 2018, Science.
[13] J. Baeten,et al. Current and future contraceptive options for women living with HIV , 2018, Expert opinion on pharmacotherapy.
[14] E. Jaffee,et al. Tumor Mutational Burden and Response Rate to PD-1 Inhibition. , 2017, The New England journal of medicine.
[15] Angela E. Leek,et al. Allele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution , 2017, Cell.
[16] S. Slovin. The need for immune biomarkers for treatment prognosis and response in genitourinary malignancies. , 2017, Biomarkers in medicine.
[17] H. Moch,et al. Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives. , 2017, Current drug metabolism.
[18] S. Signoretti,et al. Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. , 2017, European Urology.
[19] N. Chaput,et al. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine. , 2017, European journal of cancer.
[20] Dana Pe’er,et al. Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade , 2017, Cell.
[21] A. Vincent-Salomon,et al. LBA9Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of minal breast cancer. Results of the UNICANCER-eoPAL study , 2017 .
[22] C. Porta,et al. CheckMate 214: Efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups , 2017, Annals of Oncology.
[23] A. Iyer,et al. PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome , 2017, Front. Pharmacol..
[24] J. Taube,et al. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer , 2017, JAMA oncology.
[25] M. Atkins,et al. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[26] J. Cheville,et al. Clear Cell Type A and B Molecular Subtypes in Metastatic Clear Cell Renal Cell Carcinoma: Tumor Heterogeneity and Aggressiveness. , 2017, European urology.
[27] A. Ravaud,et al. IMmotion150: A phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun). , 2017 .
[28] G. Iyer,et al. Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response. , 2017 .
[29] J. Wolchok,et al. DNA damage repair and response (DDR) gene alterations (alt) and response to PD1/PDL1 blockade in platinum-treated metastatic urothelial carcinoma (mUC). , 2017 .
[30] Robert Damoiseaux,et al. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression , 2017, Cell reports.
[31] I. Wistuba,et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer , 2017, Nature Medicine.
[32] B. Escudier,et al. Nivolumab in renal cell carcinoma: latest evidence and clinical potential , 2017, Therapeutic advances in medical oncology.
[33] C. Zahnow,et al. Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer. , 2017, Cancer discovery.
[34] E. Plimack,et al. Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma , 2017, Current Treatment Options in Oncology.
[35] J. Wargo,et al. Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.
[36] T. Graeber,et al. Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations. , 2017, Cancer discovery.
[37] F. Hirsch,et al. PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[38] D. Rimm,et al. A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1 , 2017, JAMA oncology.
[39] Alan Sharpe,et al. Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non–Small Cell Lung Cancer , 2017, Clinical Cancer Research.
[40] Russell Bonneville,et al. Performance evaluation for rapid detection of pan-cancer microsatellite instability with MANTIS , 2016, Oncotarget.
[41] H. Wanibuchi,et al. Anti‐PD‐L1 treatment enhances antitumor effect of everolimus in a mouse model of renal cell carcinoma , 2016, Cancer science.
[42] Yu Shyr,et al. Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade , 2016, Cancer Immunology Research.
[43] P. Hegde,et al. Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[44] E. V. Van Allen,et al. Tumor Mutational Load and Immune Parameters across Metastatic Renal Cell Carcinoma Risk Groups , 2016, Cancer Immunology Research.
[45] Ludmila V. Danilova,et al. The Intratumoral Balance between Metabolic and Immunologic Gene Expression Is Associated with Anti–PD-1 Response in Patients with Renal Cell Carcinoma , 2016, Cancer Immunology Research.
[46] P. Stephens,et al. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations. , 2016, European urology.
[47] T. Graeber,et al. Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma. , 2016, The New England journal of medicine.
[48] E. Scarpi,et al. Systemic immune-inflammation index predicts the clinical outcome in patients with metastatic renal cell cancer treated with sunitinib , 2016, Oncotarget.
[49] P. Humphrey,et al. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours. , 2016, European urology.
[50] P. Mazzanti,et al. Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: Recent insights and future challenges. , 2016, Cancer treatment reviews.
[51] J. Kucharczyk,et al. Emerging Immunotargets in Metastatic Renal Cell Carcinoma. , 2016, Current drug targets.
[52] H. Moch,et al. An Overview of Emerging Immunotargets of Genitourinary Tumors. , 2016, Current drug targets.
[53] R. Montironi,et al. Editorial (Thematic Issue: Emerging Immunotargets in Genitourinary Tumors) , 2016 .
[54] R. Montironi,et al. Testing PD-1/PD-L1 Expression in Cancer Therapy: Pathologic Insights and Economic Sustainability. , 2016, Archives of pathology & laboratory medicine.
[55] Ana C Anderson,et al. Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation. , 2016, Immunity.
[56] P. Ross-Macdonald,et al. Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma , 2016, Clinical Cancer Research.
[57] C. Porta,et al. Prognostic Role of PD-L1 Expression in Renal Cell Carcinoma. A Systematic Review and Meta-Analysis , 2016, Targeted Oncology.
[58] Chris Sander,et al. Multilevel Genomics-Based Taxonomy of Renal Cell Carcinoma. , 2016, Cell reports.
[59] Shohei Koyama,et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints , 2016, Nature Communications.
[60] Steven J. M. Jones,et al. Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. , 2016, The New England journal of medicine.
[61] M. Meyerson,et al. Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC). , 2016 .
[62] R. Montironi,et al. New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors , 2016, Expert opinion on drug metabolism & toxicology.
[63] P. Kantoff,et al. Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[64] A. Ravaud,et al. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.
[65] D. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. , 2015, European urology.
[66] J. Larkin,et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. , 2015, The Lancet. Oncology.
[67] G. Santoni,et al. Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells , 2015, Oncotarget.
[68] R. Montironi,et al. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma , 2015, Oncotarget.
[69] Guosheng Feng,et al. Clinicopathological and prognostic value of programmed death ligand-1 (PD-L1) in renal cell carcinoma: a meta-analysis. , 2015, International journal of clinical and experimental medicine.
[70] Ming-Sound Tsao,et al. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer: In what state is this art? , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[71] Bert Vogelstein,et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.
[72] R. Raman,et al. Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review , 2015, BioMed research international.
[73] F. Massari,et al. The immunocheckpoints in modern oncology: the next 15 years , 2015, Expert opinion on biological therapy.
[74] G. Freeman,et al. Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma , 2015, Cancer Immunology Research.
[75] R. Montironi,et al. Present and future of personalized medicine in adult genitourinary tumors. , 2015, Future oncology.
[76] R. Motzer,et al. Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[77] Q. Ding,et al. Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation , 2015, Tumor Biology.
[78] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[79] M. Azuma,et al. Intrinsic and extrinsic control of expression of the immunoregulatory molecule PD-L1 in epithelial cells and squamous cell carcinoma. , 2015, Oral oncology.
[80] C. Porta,et al. PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. , 2015, Cancer treatment reviews.
[81] S. Signoretti,et al. Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial , 2014, Clinical Cancer Research.
[82] Lawrence A. Donehower,et al. The somatic genomic landscape of chromophobe renal cell carcinoma. , 2014, Cancer cell.
[83] Yong-Koo Park,et al. Deficiency of MSH2 expression is associated with clear cell renal cell carcinoma , 2014, Oncology letters.
[84] G. Nabi,et al. Chromosome 9p deletion in clear cell renal cell carcinoma predicts recurrence and survival following surgery , 2014, British Journal of Cancer.
[85] M. Kattan,et al. ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. , 2014, European urology.
[86] G. Santoni,et al. Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR‐TKIs and mTOR inhibitor , 2014, International journal of cancer.
[87] J. Taube,et al. Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy , 2014, Clinical Cancer Research.
[88] R. Motzer,et al. Randomized phase III trial of temsirolimus versus sorafenib as second-line therapy after sunitinib in patients with metastatic renal cell carcinoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] R. Montironi,et al. Heterogeneous drug target expression as possible basis for different clinical and radiological response to the treatment of primary and metastatic renal cell carcinoma: suggestions from bench to bedside , 2014, Cancer and Metastasis Reviews.
[90] H. Koblish,et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment , 2014, Journal of Immunotherapy for Cancer.
[91] Z. Trajanoski,et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. , 2013, Immunity.
[92] R. Montironi,et al. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma , 2013, Cancer Immunology, Immunotherapy.
[93] J. Reeves,et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.
[94] The Cancer Genome Atlas Research Network. COMPREHENSIVE MOLECULAR CHARACTERIZATION OF CLEAR CELL RENAL CELL CARCINOMA , 2013, Nature.
[95] Steven J. M. Jones,et al. Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.
[96] R. Motzer,et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. , 2013, The Lancet. Oncology.
[97] Lauren McCann,et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update. , 2013, European journal of cancer.
[98] G. Santoni,et al. Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity. , 2012, Recent patents on anti-infective drug discovery.
[99] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[100] A. Hartmann,et al. Mismatch Repair Proteins hMLH1 and hMSH2 Are Differently Expressed in the Three Main Subtypes of Sporadic Renal Cell Carcinoma , 2012, Pathobiology.
[101] Huanming Yang,et al. Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma , 2011, Nature Genetics.
[102] Yanjie He,et al. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2 , 2011, Journal of Cancer Research and Clinical Oncology.
[103] P. A. Futreal,et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma , 2010, Nature.
[104] E. Tartour,et al. A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients , 2010, Journal of immunotherapy.
[105] J. Shamash,et al. The Effect of Sunitinib on Immune Subsets in Metastatic Clear Cell Renal Cancer , 2010, Urologia Internationalis.
[106] Norbert Hollaender,et al. Phase 3 trial of everolimus for metastatic renal cell carcinoma , 2010, Cancer.
[107] Gyan Bhanot,et al. Molecular Stratification of Clear Cell Renal Cell Carcinoma by Consensus Clustering Reveals Distinct Subtypes and Survival Patterns. , 2010, Genes & cancer.
[108] Gurpreet W. Tang,et al. Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes , 2009, Nature.
[109] Ming-Chih Crouthamel,et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors , 2009, British Journal of Cancer.
[110] Apurva A Desai,et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] A. S. Salinas-Sánchez,et al. Implications of mismatch repair genes hMLH1 and hMSH2 in patients with sporadic renal cell carcinoma , 2008, BJU international.
[112] P. Brossart,et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. , 2008, Blood.
[113] S. Rosenberg,et al. Ipilimumab (Anti-CTLA4 Antibody) Causes Regression of Metastatic Renal Cell Cancer Associated With Enteritis and Hypophysitis , 2007, Journal of immunotherapy.
[114] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[115] Robert D. Schreiber,et al. Interferons, immunity and cancer immunoediting , 2006, Nature Reviews Immunology.
[116] Tasuku Honjo,et al. PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells , 2004, Cancer Research.
[117] R. Dahiya,et al. DNA mismatch repair genes in renal cell carcinoma. , 2003, The Journal of urology.
[118] F. Leach,et al. Mismatch Repair Gene Mutations in Renal Cell Carcinoma , 2002, Cancer biology & therapy.
[119] D. Parent-Massin,et al. Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. , 2001, Toxicology in vitro : an international journal published in association with BIBRA.
[120] Drug Combo Bests Sunitinib in RCC. , 2018, Cancer discovery.
[121] Antonio Lopez-Beltran,et al. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity. , 2015, European urology.
[122] K. Kinzler,et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints , 2015, Journal of Immunotherapy for Cancer.
[123] C. Porta,et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[124] M Aguet,et al. The IFN gamma receptor: a paradigm for cytokine receptor signaling. , 1997, Annual review of immunology.